ECA Stack (Ephedrine / Caffeine / Aspirin)
Weight Management
In plain English
The "ECA stack" combines ephedrine (a stimulant), caffeine, and sometimes aspirin to speed up metabolism and blunt appetite for weight loss. Controlled studies do show modest weight loss, but there is a real safety cost: ephedra/ephedrine raised the risk of heart palpitations, high blood pressure, psychiatric symptoms, and rare serious cardiovascular events, which led the FDA to ban ephedra-containing supplements in 2004. It is not appropriate for people with heart disease, high blood pressure, anxiety, or many other conditions, and requires careful medical oversight.
The science
The ephedrine-caffeine combination produces thermogenesis and appetite suppression via sympathomimetic activity (ephedrine stimulates adrenergic receptors and norepinephrine release; caffeine antagonizes adenosine and inhibits phosphodiesterase; aspirin was historically added to prolong the effect). A 6-month randomized controlled trial of an ephedra/caffeine product produced greater weight loss than placebo (Boozer et al., 2002). However, a comprehensive meta-analysis (Shekelle et al., JAMA 2003) found only modest short-term weight loss and a two- to three-fold increase in psychiatric, autonomic, gastrointestinal, and palpitation symptoms; safety concerns led the FDA to prohibit ephedra-containing dietary supplements in 2004. Contraindicated in cardiovascular disease, hypertension, arrhythmia, hyperthyroidism, anxiety disorders, and with MAO inhibitors; requires medical supervision.
References
- Boozer CN et al., Int J Obes 2002 (6-month RCT, ephedra/caffeine)
- Shekelle PG et al., JAMA 2003 (efficacy and safety meta-analysis)